MX2021005566A - Compuesto de 1,3,4-oxadiazolona y farmaco. - Google Patents

Compuesto de 1,3,4-oxadiazolona y farmaco.

Info

Publication number
MX2021005566A
MX2021005566A MX2021005566A MX2021005566A MX2021005566A MX 2021005566 A MX2021005566 A MX 2021005566A MX 2021005566 A MX2021005566 A MX 2021005566A MX 2021005566 A MX2021005566 A MX 2021005566A MX 2021005566 A MX2021005566 A MX 2021005566A
Authority
MX
Mexico
Prior art keywords
present
pim
compound
inhibiting activity
medicine
Prior art date
Application number
MX2021005566A
Other languages
English (en)
Inventor
Takeo Kikuchi
Hirotaka KAMITANI
Hisaaki ZAIMOKU
Yoshinari Haruta
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2021005566A publication Critical patent/MX2021005566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El propósito de la presente invención es proporcionar un compuesto que tenga actividad inhibidora de PIM. Los ejemplos del compuesto de acuerdo con la presente invención incluyen un compuesto de 1,3,4-oxadiazolona representado por la fórmula [1], y sus sales y solvatos farmacéuticamente aceptables. (ver Fórmula) El compuesto de acuerdo con la presente invención tiene actividad inhibidora de PIM. Debido a que tiene la actividad inhibidora de PIM, el compuesto de acuerdo con la presente invención es útil como un agente terapéutico para lupus eritematoso sistémico, nefritis lúpica, etc.
MX2021005566A 2018-11-15 2019-11-14 Compuesto de 1,3,4-oxadiazolona y farmaco. MX2021005566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018214950 2018-11-15
PCT/JP2019/044615 WO2020100959A1 (ja) 2018-11-15 2019-11-14 １，３，４－オキサジアゾロン化合物及び医薬

Publications (1)

Publication Number Publication Date
MX2021005566A true MX2021005566A (es) 2021-07-15

Family

ID=70731909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005566A MX2021005566A (es) 2018-11-15 2019-11-14 Compuesto de 1,3,4-oxadiazolona y farmaco.

Country Status (19)

Country Link
US (1) US20220024921A1 (es)
EP (1) EP3882239A4 (es)
JP (1) JP7434172B2 (es)
KR (1) KR20210091767A (es)
CN (1) CN113302184A (es)
BR (1) BR112021009198A2 (es)
CA (1) CA3117550A1 (es)
CL (1) CL2021001275A1 (es)
CO (1) CO2021007442A2 (es)
EA (1) EA202191349A1 (es)
EC (1) ECSP21034281A (es)
IL (1) IL282999A (es)
MA (1) MA54243A (es)
MX (1) MX2021005566A (es)
PE (1) PE20211283A1 (es)
PH (1) PH12021551103A1 (es)
SG (1) SG11202104371XA (es)
TW (1) TWI840448B (es)
WO (1) WO2020100959A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117285459B (zh) * 2023-11-24 2024-02-27 上海美迪西生物医药股份有限公司 一种小分子激酶抑制剂化合物的制备方法
CN118515653A (zh) * 2024-07-23 2024-08-20 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01139581A (ja) * 1987-08-20 1989-06-01 Nissan Chem Ind Ltd テトラヒドロフタルイミド誘導体、その製法および除草剤
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1797040A1 (en) 2004-09-29 2007-06-20 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20080086006A1 (en) 2004-12-22 2008-04-10 Nelson Todd D Process for Making Substituted Piperidines
EP2259678A4 (en) * 2008-02-29 2011-07-27 Cylene Pharmaceuticals Inc PROTEIN KINASE MODULATORS
GB0813740D0 (en) 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
MX2013006467A (es) * 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013182546A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
GB201814151D0 (en) * 2018-08-31 2018-10-17 Ucl Business Plc Compounds

Also Published As

Publication number Publication date
SG11202104371XA (en) 2021-05-28
ECSP21034281A (es) 2021-06-30
IL282999A (en) 2021-06-30
PH12021551103A1 (en) 2021-11-22
EA202191349A1 (ru) 2021-08-10
CA3117550A1 (en) 2020-05-22
MA54243A (fr) 2021-09-22
BR112021009198A2 (pt) 2021-08-03
EP3882239A4 (en) 2022-08-10
TW202031649A (zh) 2020-09-01
US20220024921A1 (en) 2022-01-27
AU2019381493A1 (en) 2021-06-03
CL2021001275A1 (es) 2021-11-05
KR20210091767A (ko) 2021-07-22
JPWO2020100959A1 (ja) 2021-10-07
WO2020100959A1 (ja) 2020-05-22
PE20211283A1 (es) 2021-07-19
JP7434172B2 (ja) 2024-02-20
CN113302184A (zh) 2021-08-24
TWI840448B (zh) 2024-05-01
EP3882239A1 (en) 2021-09-22
CO2021007442A2 (es) 2021-06-21

Similar Documents

Publication Publication Date Title
SA520420033B1 (ar) مركبات صيدلية
PH12020551821A1 (en) Novel compounds
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2015010971A (es) Derivado novedoso de pirazol.
MX2021011606A (es) Compuestos dirigidos a prmt5.
PH12017501652B1 (en) Kv1.3 inhibitors and their medical application
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
PH12021551103A1 (en) 1,3,4-oxadiazolone compound and medicine
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2021012105A (es) Compuestos de pirrol.
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
TN2016000491A1 (en) Carboxamide derivatives.
TN2016000489A1 (en) Carboxamide derivatives.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
SA520420037B1 (ar) مركب حلقي من ميثيل لاكتام واستخدامه صيدلانيًا
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2019011182A (es) Combinacion de derivados de isoindolinona con sgi-110.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4